Abstract
With the discovery that the highly effective anti-CD20 antibody therapies developed to deplete CD20+ B cells deplete CD20+ T cells equally well, a great interest in the biological properties of CD20+ T cells has emerged. In this study we show that CD20+ T cells have a proinflammatory Th1/Tc1 phenotype with a high proliferative capacity to CNS antigens. We also found that the percentage of CD20+ T cells is increased in the blood of patients with multiple sclerosis and are enriched in the CSF of the patients. Furthermore, we found a positive correlation between CD20+ T cells in the CSF and multiple sclerosis disease severity and see that regulation of CD20+ T cells likely contributes to the positive treatment effect of the multiple sclerosis treatment alemtuzumab. These data represent an important contribution to the understanding of the nature of CD20+ T cells and strongly suggests a role of CD20+ T cells in the pathogenesis of multiple sclerosis.
Original language | English |
---|---|
Journal | Brain |
Volume | 142 |
Issue number | 1 |
Pages (from-to) | 120-132 |
Number of pages | 13 |
ISSN | 0006-8950 |
DOIs | |
Publication status | Published - 1 Jan 2019 |
Keywords
- Adult
- Alemtuzumab/therapeutic use
- Antigens, CD20/blood
- Cell Proliferation/drug effects
- Cytokines/metabolism
- Female
- Flow Cytometry
- Humans
- Male
- Middle Aged
- Multiple Sclerosis/blood
- Multiple Sclerosis, Chronic Progressive/blood
- T-Lymphocytes/drug effects
- Young Adult